Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nephroblastoma trial of postoperative doxorubicin versus no doxorubicin
NL-OMON23585Recruiting
- Sponsor
- Emma Kinderziekenhuis AMC, Amsterdam (the Netherlands). UKCCSG Data Centre, University of Leicester (UK); Universitätsklinik für Kinder- und Jugendsmedizin (Germany). Séverine Guillemaut, Unité de Biostatistiques et d'Evaluation des Thérapeutiques (France).
- Start
- Jun 2002
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of doxorubicin in Wilms' tumor (2 arms), sponsored by Emma Kinderziekenhuis AMC, Amsterdam (the Netherlands). UKCCSG Data Centre, University of Leicester (UK); Universitätsklinik für Kinder- und Jugendsmedizin (Germany). Séverine Guillemaut, Unité de Biostatistiques et d'Evaluation des Thérapeutiques (France). Primary endpoint: Event Free Survival. Started Jun 2002; status: recruiting.
02
Drugs
doxorubicin
03
Conditions
Wilms' tumor
Beyond the preview
Go deeper on NL-OMON23585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23585.